Printer Friendly

Nasal, pharyngeal, and laryngeal pemphigus vulgaris successfully treated with rituximab.

Pemphigus vulgaris is a potentially fatal autoimmune blistering disease that can involve the nasopharyngeal and laryngeal tissues. The disease can be recalcitrant to conventional oral treatments, and treatment alternatives are limited. This retrospective study evaluated the efficacy of rituximab as a rescue agent in 5 patients with recalcitrant pemphigus vulgaris involving nasopharyngeal and laryngeal mucosa. All 5 patients were unresponsive to systemic steroids and at least one conventional oral immunosuppressive agent. The patients received rituximab infusions as a rescue agent because of recalcitrant disease. All 5 patients had a complete clinical response to rituximab and could discontinue systemic steroids and reduce the dosage of their initial immunosuppressive agent. No major adverse reactions were observed or reported with rituximab. Rituximab can be used as an effective rescue agent in the treatment of severe pemphigus vulgaris with nasopharyngeal and laryngeal involvement.

Naveed Sami, MD

COPYRIGHT 2017 Vendome Group LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Sami, Naveed
Publication:Ear, Nose and Throat Journal
Article Type:Report
Date:Apr 1, 2017
Previous Article:Large pediatric maxillary dentigerous cysts presenting with sinonasal and orbital symptoms: a case series.
Next Article:Role of intraoperative ropivacaine in adult post-tonsillectomy pain control: a randomized controlled trial.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters